Get started
Author

Ana Carolina Veneziani

Observed names: A.C. Veneziani, Ana C Veneziani, Ana C. Veneziani, Ana Veneziani
ORCID: 0000-0003-3980-034X
Observed ORCID: 0000-0003-3980-034X
OpenAlex ID: A5050344222
Heterogeneity and treatment landscape of ovarian carcinoma
2023 · Ana C. Veneziani, Eduardo Gonzalez-Ochoa, et al. · Nature Reviews Clinical Oncology · 212
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
2023 · Eduardo Gonzalez-Ochoa, Ana C Veneziani, et al. · Clinical Medicine Insights Oncology · 39
Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
2023 · Ana C. Veneziani, Clare Scott, et al. · Therapeutic Advances in Medical Oncology · 27
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
2024 · Carien L Creutzberg, Jae-Weon Kim, et al. · The Lancet Oncology · 24
A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives
2024 · Carlos Diego Holanda Lopes, Camila Braganca Xavier, et al. · Journal of Immunotherapy and Precision Oncology · 10
Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile
2024 · Ana C. Veneziani, Suku Sneha, et al. · Clinical Cancer Research · 10
PDF
Discrepancies in breast cancer’s oncological outcomes between public and private institutions in the southeast region of Brazil: a retrospective cohort study
2023 · Diocésio Alves Pinto Andrade, Ana Carolina Veneziani, et al. · Frontiers in Oncology · 10
PDF
Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial.
2022 · Ana Veneziani, Stephanie Lheureux, et al. · Journal of Clinical Oncology · 10
Emerging peptide therapeutics for the treatment of ovarian cancer
2023 · Ana C. Veneziani, Eduardo Gonzalez-Ochoa, et al. · Expert Opinion on Emerging Drugs · 7
Prognostic value of circulating tumor DNA for minimal residual disease detection in ovarian cancer: A systematic review and meta-analysis
2026 · Mariana Macambira Noronha, Mariana Carvalho Gouveia, et al. · Critical Reviews in Oncology/Hematology · 2
Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancers
2024 · Ainhoa Madariaga, Nazlin Jivraj, et al. · International Journal of Gynecological Cancer · 2
Taking the Road Less Traveled: Following Molecular Trail Markers
2022 · Ana C. Veneziani, Amit M. Oza · Clinical Cancer Research · 2
Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer
2026 · Kim Ma, Basile Tessier-Cloutier, et al. · Current Oncology · 1
Phase Ib expansion and dose optimization study of CX-5461 in patients with solid tumours enriched for DNA-repair deficiencies.
2026 · Ana Veneziani, Stephanie Lheureux, et al. · Journal of Clinical Oncology · 1
Immune checkpoint inhibitors in clear cell ovarian carcinoma and mixed gynecologic clear cell cohorts: a systematic review and meta-analysis
2026 · Mariana Macambira Noronha, Luiz Felipe Costa de Almeida, et al. · International Journal of Gynecological Cancer · 1
Abstract A074: Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 PESCO Trial
2024 · Ana C. Veneziani, Husam Alqaisi, et al. · Cancer Research · 1
Prognosis of Hpv-negative Cervical Cancer: a Systematic Review and Meta-analysis
2026 · Laura Venegas, Mariana Noronha, et al. · International Journal of Gynecological Cancer
The evolving role of immunotherapy in ovarian cancer
2026 · Ana Carolina Veneziani, Laura Venegas, et al. · Cancer
PDF
Antibody-drug conjugates and beyond in platinum-resistant ovarian cancer: A comprehensive review of emergent strategies
2026 · Mariana Macambira Noronha, Luiz Felipe Costa de Almeida, et al. · Therapeutic Advances in Medical Oncology
Abstract A059: Phase I study of the PKMYT1 inhibitor RP-6306 (lunresertib) in combination with carboplatin and paclitaxel for recurrent p53-abnormal ovarian and uterine cancer (GyneRep / OZUHN-019)
2026 · Laura Venegas, Pamela Soberanis, et al. · Clinical Cancer Research
From intensification to selection: the next challenge in advanced or recurrent endometrial cancer
2026 · Teresa Zumarraga, Ana C. Veneziani, et al. · International Journal of Gynecological Cancer
Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting
2026 · Ainhoa Madariaga, Ana Veneziani, et al. · International Journal of Gynecological Cancer
Refractory ultra–high-risk Choriocarcinoma achieving complete response to intensive multi-agent and intrathecal chemotherapy and anti–PD-L1 therapy
2026 · Laura Venegas, Brooke Grant, et al. · Gynecologic Oncology Reports
Vaccine-induced immune responses, HLA genotyping, and molecular profiling in patients with metastatic ovarian cancer (the PESCO trial).
2026 · Ana Veneziani, Douglas G. Millar, et al. · Journal of Clinical Oncology
PDF
Enhancing supportive care in malignant bowel obstruction: A QI project using virtual dietitian-led low-fiber diet education.
2026 · Bojan Macanovic, Vikas Garg, et al. · Journal of Clinical Oncology
Works count: 38
Citation count: 358
H-index: 8
I10-index: 8
Year
Topic
Type